Vaccine News and Research

Latest Vaccine News and Research

GeoVax Labs announces financial results and operational update for the third quarter of 2009

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update.

6 Nov 2009

Swine flu vaccine distribution to New York companies causes uproar

The distribution of swine flu vaccines to big name companies in New York has caused an uproar as people complain that children and health care workers should receive top priority. The New York Times reports: "New York City health officials have distributed small amounts of the swine flu vaccine to some major New York companies, including Wall Street banks like Goldman Sachs and Citigroup, even as shortages continue.

6 Nov 2009

55% of adult population in Greater Washington, DC say they will not get H1N1 flu vaccine, reveals poll results

Fifty-five percent of the adult population in the Greater Washington, DC region say they will not get the H1N1 flu vaccine, according to a new poll commissioned by the Greater Washington Board of Trade.

6 Nov 2009

H1N1 is now most dominant flu strain worldwide, WHO says

The H1N1 (swine flu) virus is now the dominant flu strain worldwide, the WHO reported Thursday, with the virus accounting for up to 70 percent of the flu viruses sampled in some countries, the Associated Press reports.

6 Nov 2009

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009.

6 Nov 2009

First Edition: October 6, 2009

Today's headlines highlight activity on different fronts -- with House Democrats scrambling to hold together fragile support for tomorrow's health bill vote while Republican lawmakers and other health reform opponents intensify their attack.

6 Nov 2009

UTSA releases its newest research numbers

The University of Texas at San Antonio (UTSA) released its newest research numbers today, reporting a 34% increase to $46,521,487 in total research spending for the Sept. 1, 2008 – Aug. 31, 2009 fiscal year (FY 09) over the previous fiscal year, when research spending totaled $34,601,444. The statistic is up 97% from just five years ago, when UTSA’s total research expenditures were $23,605,844.

6 Nov 2009

CREW urge HHS to investigate CDC's approval to distribute H1NI vaccine to Wall Street firms

Today, Citizens for Responsibility and Ethics in Washington (CREW) asked Health and Human Service (HHS) Secretary Kathleen Sebelius to investigate why the Center for Disease Control (CDC) approved the distribution of the H1NI vaccine to Wall Street firms at a time when the vaccine is unavailable to most Americans.

6 Nov 2009

Eggs sensitivity and flu shot: Doctors' dilemma

"My three year old had a skin breakout we think was due to eggs - is it safe to do a flu shot?" It's a question being asked to every doctor who takes care of kids during flu season. "On the one hand we are concerned about the devastating effects of the new strain of flu, and on the other we aren't sure if a history of eggs sensitivity is enough to hold the shot or spray," said Bobby Q. Lanier, M.D., clinical professor of pediatrics at the University of North Texas HSC in Fort Worth, Texas, and executive medical director of the American College of Allergy, Asthma and Immunology (ACAAI).

6 Nov 2009

Journal of Infectious Diseases' special edition on rotavirus

The Journal of Infectious Diseases has released a special edition, Global Rotavirus Surveillance: Preparing for the Introduction of Rotavirus Vaccines. This special edition provides a significant contribution to the understanding of rotavirus disease burden and the impact of rotavirus vaccines, which have the potential to save an estimated 228,000 lives annually.

6 Nov 2009

New advance in healthcare collaboration between CII and USIBC announced

The Confederation of Indian Industry and the U.S.-India Business Council today announced a major new advance in healthcare collaboration, partnering under the banner of the USIBC-led “Coalition for Healthy India”.

6 Nov 2009

Physicians concern about the spread of H1N1 virus and the availability of H1N1 vaccine

According to a Panel Intelligence survey of 50 primary care physicians, there are significant concerns about the H1N1 virus not just in terms of disease prevalence and vaccine shortages, but also in that 38% of the physicians surveyed (PCPs, pediatricians, and gerontologists) are "very concerned" about the virus evolving into a more serious strain and another 52% have moderate concerns about such a development.

6 Nov 2009

Alliance Québécoise du Psoriasis provides information concerning H1N1 vaccination campaign

The Alliance Québécoise du Psoriasis (Quebec psoriasis alliance) would like to give its members and other psoriasis sufferers information concerning the massive H1N1 vaccination campaign.

6 Nov 2009

Unum enhances the wellness benefit of its critical illness products by adding H1N1 vaccine

Unum has enhanced the wellness benefit of its critical illness products by adding the H1N1 vaccine to the list of qualifying procedures.

6 Nov 2009

Walls Street journal examines big pharma's 'growing interest' in emerging-market vaccine development, production

The Wall Street Journal examines "big pharma's growing interest in a corner of healthcare - emerging-market inoculations," in light of a recent move by Novartis to purchase an 85 percent stake in the Chinese vaccine maker Zhejiang Tianyuan Bio-Pharmaceutical Co. In the summer, drug maker Sanofi-Aventis SA made a similar move to acquire a majority stake in India's Shantha Biotechnics, the newspaper notes.

6 Nov 2009

HHS announces contract awards for up to 120,000 treatment courses of intravenous antiviral drugs

The U.S. Department of Health and Human Services (HHS) today announced contract awards for up to 120,000 treatment courses of intravenous (IV) antiviral drugs to help treat hospitalized 2009 H1N1 influenza patients.

6 Nov 2009

Malaria experts discuss eradication at MIM conference

In a session at the 5th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Nairobi, Kenya, experts discussed the tools required to eradicate the disease and highlighted insecticide and drug resistance in some parts of the world, Xinhua reports. Researchers noted that resistance to artemisinin-based combination therapies (ACTs) has been documented in western Cambodia and "has now also been reported in the west of Thailand and in eastern Myanmar," the news service writes (Ooko/Zhuoyun, 11/5).

6 Nov 2009

GenVec and SAIC-Frederick signs contract to develop influenza and HIV vaccines

GenVec, Inc, announced today that SAIC-Frederick, Inc. has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

5 Nov 2009

U.S. health officials offer no prediction of when all high-risk groups will have access to H1N1 vaccine

U.S. health officials briefing Congress on Wednesday would not outline a timeline for when enough H1N1 (swine flu) vaccines would be available to reach all high-risk populations in the country, the Washington Post reports.

5 Nov 2009

Also in global health news: Kenya child mortality; DRC rape; Cape Verde dengue outbreak; Guatemala malnutrition; East Africa flooding

"The most current data from the Kenya National Bureau of Statistics under the Demographic and Health Survey (DHS) launched on Wednesday shows mortality among children under five years stands at 7.4 percent, while that of infants is at 5.2 percent," Business Daily reports.

5 Nov 2009

Vaccine News and Research

Latest Vaccine News and Research

GeoVax Labs announces financial results and operational update for the third quarter of 2009

Swine flu vaccine distribution to New York companies causes uproar

55% of adult population in Greater Washington, DC say they will not get H1N1 flu vaccine, reveals poll results

H1N1 is now most dominant flu strain worldwide, WHO says

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

First Edition: October 6, 2009

UTSA releases its newest research numbers

CREW urge HHS to investigate CDC's approval to distribute H1NI vaccine to Wall Street firms

Eggs sensitivity and flu shot: Doctors' dilemma

Journal of Infectious Diseases' special edition on rotavirus

New advance in healthcare collaboration between CII and USIBC announced

Physicians concern about the spread of H1N1 virus and the availability of H1N1 vaccine

Alliance Québécoise du Psoriasis provides information concerning H1N1 vaccination campaign

Unum enhances the wellness benefit of its critical illness products by adding H1N1 vaccine

Walls Street journal examines big pharma's 'growing interest' in emerging-market vaccine development, production

HHS announces contract awards for up to 120,000 treatment courses of intravenous antiviral drugs

Malaria experts discuss eradication at MIM conference

GenVec and SAIC-Frederick signs contract to develop influenza and HIV vaccines

U.S. health officials offer no prediction of when all high-risk groups will have access to H1N1 vaccine

Also in global health news: Kenya child mortality; DRC rape; Cape Verde dengue outbreak; Guatemala malnutrition; East Africa flooding

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vaccine News and Research

Latest Vaccine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in